ey Home | Marketa | Saving & banking | Investing | Bills | Cars | Holidays | Cards & Ioans | Pensions | Mortgages | Experts | Buy-to-let



## SMALL CAP MOVERS: ImmuPharma nearly trebles in value as US deal resurrects flagship lupus drug

By CALUM MUIRHEAD AT PROACTIVE INVESTORS FOR THISISMONEY

PUBLISHED: 12:32, 29 November 2019 | UPDATED: 12:33, 29 November 2019


















AIM saw a resurrection this week as small cap biotech ImmuPharma secured a deal worth almost \$100million for Lupuzor, its treatment for the autoimmune disease. lupus.

US speciality drugs group Avion Pharmaceuticals will fund the \$25million in costs of a reformatted phase III clinical trial next year following the agreement of a trial design with the US Food & Drug Administration.

The UK group will receive up to \$70million of milestone payments, with \$5million due on regulatory approval of the product and a further \$65million dependent on sales targets.




On the up: ImmuPharma secures deal for Lupuzor its treatment for lupus



## CHECK YOUR INVESTMENTS

- Stock market latest



## Vanguard STANLEY. Direct 0.25% annual fee, no 0.15% per year fee, no

dealing charge dealing charge

tree fund dealing l'ensions & lass



£7.50 share and

Online investment

CHARLES